Galapagos NV: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Galapagos NV Confirms FY 2013 Revenue Guidance; Galapagos NV's Argenta Collaborates with Antabio and Boehringer Ingelheim; Acquires Cangenix
Galapagos NV announced that it reiterates its fiscal year 2013 guidance for Group revenues of EUR160 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of EUR 163.43 million. The Company also announced that its subsidiary Argenta signed a collaboration agreement with Antabio for the identification of anti-bacterial agents and discovery of a development candidate. Argenta also signed an integrated drug discovery collaboration with Boehringer Ingelheim. In addition, Arganta acquired Cangenix, a structure-based drug discovery company. The financial terms of the deal were not disclosed.
Latest Key Developments in Biotechnology
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Share this
- Digg this